US 12,391,755 B2
Methods of use for anti-ILT2 antibodies
Ilana Mandel, Karmiel (IL); Tsuri Peretz, Kiryat Tivon (IL); Dana Haves Ziv, Karmiel (IL); Ilana Goldshtein, Misgav (IL); Dror Alishekevitz, Kiryat Tivon (IL); Anna Fridman-Dror, Kibbutz Dalia (IL); Motti Hakim, Kibbutz Gazit (IL); Avidor Shulman, Rakefet (IL); Yair Sapir, Manof (IL); and Tehila Ben-Moshe, Tel Aviv (IL)
Assigned to Biond Biologics Ltd., Misgav (IL)
Filed by Biond Biologics Ltd., Misgav (IL)
Filed on Nov. 23, 2021, as Appl. No. 17/533,945.
Application 17/533,945 is a division of application No. 17/224,016, filed on Apr. 6, 2021, granted, now 11,236,162.
Application 17/224,016 is a continuation of application No. PCT/IL2020/050889, filed on Aug. 12, 2020.
Claims priority of provisional application 63/034,569, filed on Jun. 4, 2020.
Claims priority of provisional application 62/885,374, filed on Aug. 12, 2019.
Prior Publication US 2022/0153836 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method of inducing or enhancing an anti-tumor T-cell response, increasing T-cell proliferation, reducing cancer-induced suppressor myeloid activity, increasing natural killer cell cytotoxicity, increasing macrophage phagocytosis, increasing generation of M1 inflammatory macrophages, decreasing generation of M2 suppressor macrophages, increasing dendritic cell number in a tumor microenvironment, increasing dendritic cell activation, treating an HLA-G expressing cancer, or treating a MHC-I expressing cancer in a human subject in need thereof, comprising administering to the subject a monoclonal anti-immunoglobulin-like transcript 2 (ILT2) antibody or an antigen-binding fragment thereof, wherein the anti-ILT2 antibody comprises three heavy chain CDRs (HCDRs) and three light chain CDRs (LCDRs), wherein the HCDR1-3 and LCDR1-3 comprise:
a) SEQ ID NOs: 13-18, respectively, wherein X in SEQ ID NO: 15 is selected from A, C, and S;
b) SEQ ID NOs: 1-6, respectively; or
c) SEQ ID NOs: 7-12, respectively.
 
12. A method for treating cancer by increasing efficacy of an anti-PD-L1- or anti-PD-1-based therapy against a cancer cell expressing HLA-G, MHC-I, or both in a subject in need thereof, comprising administering to the subject a monoclonal anti-immunoglobulin-like transcript 2 (ILT2) antibody or an antigen-binding fragment thereof, wherein the anti-ILT2 antibody comprises three heavy chain CDRs (HCDRs) and three light chain CDRs (LCDRs), wherein the HCDR1-3 and LCDR1-3 comprise:
a) SEQ ID NOs: 13-18, respectively, wherein X in SEQ ID NO: 15 is selected from A, C, and S;
b) SEQ ID NOs: 1-6, respectively; or
c) SEQ ID NOs: 7-12, respectively.